Phathom Pharmaceuticals Stock Forecast, Price & News

+0.31 (+0.89 %)
(As of 06/14/2021 01:38 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,260 shs
Average Volume91,628 shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PHAT News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Phathom Pharmaceuticals logo

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.79 out of 5 stars

Medical Sector

210th out of 2,099 stocks

Pharmaceutical Preparations Industry

100th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Phathom Pharmaceuticals (NASDAQ:PHAT) Frequently Asked Questions

Is Phathom Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Phathom Pharmaceuticals stock.
View analyst ratings for Phathom Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Phathom Pharmaceuticals?

Wall Street analysts have given Phathom Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Phathom Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Phathom Pharmaceuticals?

Phathom Pharmaceuticals saw a increase in short interest during the month of May. As of May 14th, there was short interest totaling 973,700 shares, an increase of 39.6% from the April 29th total of 697,700 shares. Based on an average daily trading volume, of 98,000 shares, the days-to-cover ratio is presently 9.9 days. Approximately 6.0% of the company's shares are short sold.
View Phathom Pharmaceuticals' Short Interest

When is Phathom Pharmaceuticals' next earnings date?

Phathom Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Phathom Pharmaceuticals

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings results on Tuesday, May, 11th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.11) by $0.15.
View Phathom Pharmaceuticals' earnings history

How has Phathom Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Phathom Pharmaceuticals' stock was trading at $34.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PHAT stock has increased by 0.8% and is now trading at $35.02.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PHAT?

5 brokerages have issued 12-month target prices for Phathom Pharmaceuticals' stock. Their forecasts range from $48.00 to $63.00. On average, they anticipate Phathom Pharmaceuticals' stock price to reach $56.50 in the next twelve months. This suggests a possible upside of 61.3% from the stock's current price.
View analysts' price targets for Phathom Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Phathom Pharmaceuticals' key executives?

Phathom Pharmaceuticals' management team includes the following people:
  • Ms. Terrie J. Curran, Pres, CEO & Director (Age 52, Pay $865.85k)
  • Mr. Todd P. Branning, Chief Financial Officer (Age 51, Pay $513.62k)
  • Dr. Azmi Nabulsi M.D., M.P.H., Chief Operating Officer (Age 61, Pay $727.97k)
  • Mr. Joseph Hand J.D., Chief Admin. Officer
  • Mr. Lawrence Miller Esq., J.D., Gen. Counsel & Sec.
  • Mr. Aditya Kohli Ph.D., Chief Bus. Officer (Age 32)
  • Mr. Tom Harris, Head of Regulatory Affairs
  • Dr. Eckhard Leifke M.D., Ph.D., Chief Medical Officer
  • Mr. Martin J. Gilligan, Chief Commercial Officer

Who are some of Phathom Pharmaceuticals' key competitors?

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include (VIR), Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).

When did Phathom Pharmaceuticals IPO?

(PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Phathom Pharmaceuticals' stock symbol?

Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.94%), Janus Henderson Group PLC (6.24%), Ensign Peak Advisors Inc (3.96%), Gilder Gagnon Howe & Co. LLC (2.61%), BlackRock Inc. (2.61%) and Caas Capital Management LP (0.67%). Company insiders that own Phathom Pharmaceuticals stock include Azmi Nabulsi, David A Socks, Life Sciences Ix LP Frazier, Pharmaceutical Co Ltd Takeda, Ra Capital Management, LP and Terrie Curran.
View institutional ownership trends for Phathom Pharmaceuticals

Which institutional investors are selling Phathom Pharmaceuticals stock?

PHAT stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Millennium Management LLC, Squarepoint Ops LLC, Citadel Advisors LLC, Credit Suisse AG, Bank of New York Mellon Corp, Citigroup Inc., and Alliancebernstein L.P.. Company insiders that have sold Phathom Pharmaceuticals company stock in the last year include Azmi Nabulsi, David A Socks, Pharmaceutical Co Ltd Takeda, and Terrie Curran.
View insider buying and selling activity for Phathom Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Phathom Pharmaceuticals stock?

PHAT stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, GW&K Investment Management LLC, Caas Capital Management LP, Woodline Partners LP, Geode Capital Management LLC, Parkman Healthcare Partners LLC, Aviva PLC, and BlackRock Inc.. Company insiders that have bought Phathom Pharmaceuticals stock in the last two years include Life Sciences Ix LP Frazier, and Ra Capital Management, LP.
View insider buying and selling activity for Phathom Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phathom Pharmaceuticals' stock price today?

One share of PHAT stock can currently be purchased for approximately $35.02.

How much money does Phathom Pharmaceuticals make?

Phathom Pharmaceuticals has a market capitalization of $1.10 billion. The company earns $-129,070,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

How many employees does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals employs 55 workers across the globe.

What is Phathom Pharmaceuticals' official website?

The official website for Phathom Pharmaceuticals is

Where are Phathom Pharmaceuticals' headquarters?

Phathom Pharmaceuticals is headquartered at 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932.

How can I contact Phathom Pharmaceuticals?

Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The company can be reached via phone at 877-742-8466 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.